Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma

Inclusion Criteria: * Pathologic diagnosis of glioblastoma or grade IV glioma. * Tumor volume should be less than 60 cc (approximately 5cm maximum diameter). * Age \> or = to 18 * KPS ≥70 * Granulocyte count \>1.5 X 10 9/L * Platelet count \>99 X 10 9/L * SGOT \< 2.5X upper limit of normal (ULN) * Serum creatinine \< 2X ULN * Bilirubin \< 2X ULN * All patients must sign written informed consent Exclusion Criteria: * Any prior chemotherapy, radiotherapy and biologic therapy for glioma. * Any prior experimental therapy for glioma. * Multicentric glioma * Other concurrent active malignancy (with the exception of cervical carcinoma in situ or basal cell ca of the skin). * Serious medical or psychiatric illness that would in the opinion of the investigator interfere with the prescribed treatment. * Pregnant or breast feeding women. * Refusal to use effective contraception * Inadequately controlled hypertension (defined as systolic blood pressure \>150 mmHg and/or diastolic blood pressure \> 100 mmHg) * Prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association (NYHA) Grade II or greater congestive heart failure * History of myocardial infarction or unstable angina within 12 months prior to Day 1 * History of stroke or transient ischemic attack * Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1 * History of hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1 * Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of treatment or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1 * History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 * Serious, non-healing wound, active ulcer, or untreated bone fracture * Proteinuria as demonstrated by a UPC ratio ≥ 1.0 at screening * Known hypersensitivity to any component of bevacizumab